Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International journal of clinical practice

• Publication date

  2006-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/j.1368-5031.2006.00970.xPMID 16805746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease.

  2005cited by this paper
• Targeting acetylcholinesterase and butyrylcholinesterase in dementia.

  2005cited by this paper
• Differential Efficacy of Treatment with Acetylcholinesterase Inhibitors in Patients with Mild and Moderate Alzheimer’s Disease over a 6-Month Period

  2005cited by this paper
• Discontinuation of rivastigmine in routine clinical practice

  2005cited by this paper
• Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease

  2005cited by this paper
• Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years

  2005cited by this paper
• Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.

  2005cited by this paper
• Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

  2004cited by this paper
• Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease

  2004cited by this paper
• Rivastigmine in Alzheimer disease: efficacy over two years.

  2004cited by this paper
• Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease

  2004cited by this paper
• Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.

  2004cited by this paper
• Neuropsychological profile of Alzheimer’s disease in women: moderate and moderately severe cognitive decline

  2004cited by this paper
• Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.

  2004cited by this paper
• Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.

  2004cited by this paper
• Performance and normative values of a concise neuropsychological test (CAMCOG) in an elderly population sample

  2003cited by this paper
• Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.

  2003cited by this paper
• Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease

  2003cited by this paper
• Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

  2003cited by this paper
• Assessing the Clinical Importance of Statistically Significant Improvement in Anti-Dementia Drug Trials

  2001cited by this paper
• Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances.

  2000cited by this paper
• Early detection of Alzheimer's disease using the Cambridge Cognitive Examination (CAMCOG)

  2000cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw

  1999cited by this paper
• Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease.

  1998cited by this paper
• CAMCOG--a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample.

  1995cited by this paper
• Awareness of cognitive deficits and anosognosia in probable Alzheimer's disease.

  1994cited by this paper
• Cholinesterase Inhibitors in Alzheimer's Disease

  1994cited by this paper
• The Mini‐Mental State Examination: A Comprehensive Review

  1992cited by this paper
• Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist.

  1992cited by this paper
• CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer's disease: Nexus of cholinergic and nerve growth factor dysfunction.

  2021cites this paper
• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

  2021cites this paper
• An in vitro study on the interaction of the anti-Alzheimer drug rivastigmine with human erythrocytes.

  2020cites this paper
• Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder

  2018cites this paper
• Depression in Alzheimer’s disease: Citalopram and Rivastigmine can better?

  2017cites this paper
• A Review of Pharmacological Treatments for Depression in Alzheimer's Disease.

  2015cites this paper
• A Case for Memory Enhancement: Ethical, Social, Legal, and Policy Implications for Enhancing the Memory

  2014cites this paper
• Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia

  2011cites this paper
• Acute Inhibition of 11β-Hydroxysteroid Dehydrogenase Type-1 Improves Memory in Rodent Models of Cognition

  2011cites this paper
• Adaptive cognitive testing in dementia

  2009cites this paper
• Behavioral effects of current Alzheimer's disease treatments: A descriptive review

  2008cites this paper
• A double blind, placebo‐controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression

  2008influential citation
• Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study.

  2008cites this paper
• Current awareness in human psychopharmacology

  2007cites this paper
• Pharmacotherapy, clinical pharmacology and biomarker research in geriatric patients

  2007cites this paper
• VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.

  2007cites this paper
• Rivastigmine in the treatment of patients with Alzheimer’s disease

  2007cites this paper
• A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.

  2006cites this paper
• Discontinuation of rivastigmine in routine clinical practice

  2005cites this paper